1 - 28 of 28
Dr. Falk is a Clinical Geneticist who serves as executive director of the Mitochondrial Medicine Frontier Program. Her translational research lab investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and human tissue models of genetic-based respiratory chain dysfunction.
Dr. Feemster's research includes vaccine acceptance among parents and immunization providers, community-based interventions to improve vaccine uptake, neighborhood factors associated with the incidence of pertussis and influenza, and healthcare-associated respiratory infection in the pediatric ambulatory setting.
Dr. Fein conducts youth violence prevention research and has been the principal investigator (PI) or co-investigator of numerous federally funded projects addressing the youth violence epidemic through mixed-methods research, particularly community-based, participatory research (CBPR). He is currently the PI for a NICHD-funded study looking at the impact of a post-traumatic stress disorder (PTSD) prevention program on assault-injured youth and their families.
Dr. Felix uses molecular, biochemical, cellular and in vivo methods to investigate the pathobiology of leukemias with KMT2A (MLL) translocations. Leukemias with these translocations affect infants and young children or occur as a complication of type II topoisomerase (TOP2) poison chemotherapies used for anti-cancer treatment. She aims to develop better treatment and prevention approaches for these leukemias, which have a poor prognosis.
Dr. Feudtner's research strives to advance the well-being of pediatric patients with complex chronic conditions and serious, often rare, illnesses, and to promote the well-being of their families. Along with his colleagues, Dr. Feudtner is conducting studies focusing on pediatric palliative care, complex care, the impact on families of pediatric serious illness, and pediatric medical ethics.
Dr. Fieldston focuses on evidence-based management aimed at delivering high-value care and the impact of operational issues on patient outcomes. His academic work included investigating associations between patient flow, care models, workload and occupancy levels, and resource utilization on the quality of healthcare delivered to children, particularly those in the hospital, as well as healthcare value and value education.
Dr. Fiks’ research is aimed at improving outcomes for ambulatory pediatric patients through primary care, practice-based scholarship with a focus on improving health and healthcare decision-making through health information technology.
Dr. Fisher's research focuses on infections in children with immunocompromising conditions. He is particularly interested in infections in children with cancer and serves as the chair of the Infectious Disease Domain within the Children’s Oncology Group.
Dr. Flake is a general pediatric surgeon with a clinical and research focus on prenatal treatment ranging from the fetal surgical repair of anatomic anomalies to prenatal stem cell and gene therapy. He has extensive experience in developing rodent, canine, and sheep models for in utero transplantation and for investigating fetal surgery for anatomic malformations.
Dr. Foglia's research aims to identify the best methods to monitor and perform neonatal resuscitation, with the ultimate goal of optimizing outcomes for high risk infants who require resuscitation in the delivery room and neonatal intensive care unit setting.
Dr. Forrest's research focuses on developing novel ways of conducting multi-center pediatric applied clinical research, child health services and outcomes research, pediatric person-reported outcome measure development and application, life course health science, learning health systems science, and policies and programs that promote the lifelong health of children. He has a particular interest in the concept and measurement of health.
Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.
Dr. Freedman has a particular interest in epidemiologic and translational research within pediatric supportive oncology. He aims to advance the understanding and treatment of symptoms, infections, and organ toxicities in pediatric cancer and hematopoietic stem cell transplant patients.
Dr. French came to CHOP in 2008 to establish the Human Pluripotent Stem Cell Core in the Center for Cellular and Molecular Therapeutics. She is an internationally recognized researcher involved in multi-investigator teams that utilize pluripotent stem cells for modeling human disease to study mechanism, development, and establish new therapeutic modalities.
Dr. Furth's research focuses on defining risk factors for kidney disease progression in children; characterizing the effect of kidney function decline on neurodevelopment, cognitive abilities and behavior; identifying the prevalence and evolution of cardiovascular disease risk factors, and examining the effects of declining glomerular filtration rate on children’s growth.